Status:
UNKNOWN
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
Lead Sponsor:
Hannover Medical School
Collaborating Sponsors:
CytoSorbents, Inc
Conditions:
Cytokine Release Syndrome
CAR-T
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs). P...
Eligibility Criteria
Inclusion
- severe CRS (\> 3) and / or severe CRES (\>3)
- AND
- \- CRS/CRES onset \< 6 hrs
Exclusion
- Heparine allergy
- contraindication for anticoagulation
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04048434
Start Date
June 1 2021
End Date
September 1 2024
Last Update
April 1 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover Medical School
Hanover, Germany
2
Universitätsspital Zürich (USZ)
Zurich, Switzerland